Cambrex Exhibiting and Presenting at Biotech Outsourcing Strategies cmc2011
Alexandra Pichard Nielsen, Director, Sales and Business Development, Northern Europe
+45 51 33 58 56
East Rutherford, NJ and Copenhagen, Denmark – Cambrex Corporation (NYSE: CBM, "Cambrex") will be exhibiting and presenting at the Biotech Outsourcing Strategies cmc2011 (BOS cmc2011) in Hørsholm, Denmark, near Copenhagen. The one day conference, being held June 16, 2011 at Søhuset Conference Centre, will feature industry experts in small molecule and biopharmaceutical Custom Manufacturing Controls (CMC) development for Pharma, Biotech and Custom Research Organizations (CRO).
Cambrex will be showcasing its contract service capabilities ranging from development to finished dosage form manufacture with a portfolio of offerings that include controlled substances, high potency APIs, high energy chemistries, drug delivery and enzymatic biotransformation technologies. Cambrex manufactures over 120 generic and branded APIs, along with advanced intermediate products.
In the Biologics speaker track, Dr. Dieter Plogmann, Business Development for Cambrex IEP (Wiesbaden, Germany) will present on Biocatalysis R&D, Services and Technologies. His presentation will detail Cambrex IEP’s more than 10 years of experience developing enzyme-catalyzed biotransformations using a toolbox of more than 160 cloned and over-expressed oxidoreductases, as well as providing custom development and R&D screening services.
Cambrex IEP’s biocatalysis technology provides high yields and enantiomeric excess at commercial volumes for the manufacture of chiral amines and alcohols. By utilizing enzymatic processes to produce the desired chiral product, manufacturing and cost-efficiencies are gained versus traditional chemical synthesis. Producing the desired enantiomers in excellent yields and high enantiomeric excess eliminates processing steps including resolution which are a major source of yield loss.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.